VHH Antibody Discovery

Fast, Customised and Built for Scientists

Custom VHH Antibody discovery, delivered with speed, precision, and partnership – powered by the world’s largest synthetic VHH libraries and proprietary CIS Display™ technology.

Antibody discovery - Fast, Customised and Built for Scientists

At Isogenica, we work as a specialized extension of your team open, agile, and grounded in science. From high-throughput screening to custom VHH engineering, our approach accelerates timelines, strengthens IP, and reduces early-stage risk. Whether you’re targeting a tough indication or racing to a milestone, we help you reach inflection points with clarity and confidence. Precision. Partnerships. Progress. That’s the Isogenica difference. 

Trusted by Leading Biotech Innovators

From emerging biotechs to established pharma leaders, our partners rely on our speed, scale, and science 

What You Can Expect from Isogenica

Faster Discovery, Stronger Candidates

We deliver high-affinity, high-specificity VHHs faster – with sequence diversity and early developability data that support novelty, downstream IP potential, and better clinical starts. All without compromising scientific rigor.

CIS Display™ + Synthetic Scale

The world’s largest synthetic VHH libraries deliver 100–1000× more screening to achieve higher affinity hits. Proprietary CIS Display™ technology scales up discovery even further, deepening datasets and leading to faster timelines and stronger candidate profiles.

Built for Scientists. Backed by Cambridge.

Flexible, transparent, and science-led our collaborative model is grounded in the trusted, regulated Cambridge biotech ecosystem. We act as a true extension of your team, bringing expert input and milestone-driven execution to every programme.

Driven by Discovery. Trusted for Results.

Our team brings together decades of experience in antibody engineering, synthetic biology, and therapeutic discovery – with over 100 programmes delivered and multiple leads progressed to the clinic.  Get to know the scientists behind our platform and discover what makes Isogenica a partner of choice in antibody discovery. 

VHH Resources

Explore our VHH resources – including white papers, blog posts and webinars

A Competitive and Ethical Future in Discovery

A Competitive and Ethical Future in Discovery

Traditionally, antibody generation relied on immunizing animals (e.g. mice, rabbits, or even llamas) to raise binders against a target antigen. However, emerging synthetic antibody library technologies now allow scientists to bypass animal immunization by using in silico designed vast libraries of human or humanized antibody fragments.

Upcoming Events

Check out our upcoming events and see where we’ve been recently.

Latest News

Check out our latest news on collaborations and press releases

Explore the science behind our antibody discovery platforms

Access our latest white papers and application notes to see how Isogenica’s synthetic VHH technologies are accelerating innovation in CAR-T, bispecifics, and immuno-oncology.
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy.   Download
Extending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable. DOWNLOAD
Advantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note. DOWNLOAD
Optimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. DOWNLOAD
Isogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. DOWNLOAD
Anti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery… DOWNLOAD
Contact us